Taxotere (docetaxel) is a chemotherapy drug manufactured and marketed by Sanofi-Aventis and prescribed by many U.S. physicians to treat breast cancer patients. This drug was aggressively marketed to doctors, as it was claimed that it was more effective than other chemotherapy drugs. In 2009, the FDA issued a cease and desist letter requiring the company to stop claiming that it worked better than other chemotherapy drugs. Even though it didn’t work better than other chemotherapy drugs, and while chemotherapy often causes temporary, reversible hair loss, a significant number of taxotere patients suffered permanent hair loss. While Sanofi-Aventis acknowledged in Europe in 2005 that a significant number of patients were suffering permanent hair loss, it wasn’t until December 2015 that U.S. patients were warned about permanent hair loss. If women and their physicians had known that Taxotere wasn’t more effective than other chemotherapy drugs, and unlike the alternatives, caused permanent hair loss, it is unlikely that women and their physicians would have chosen Taxotere.
If you are a woman, who used Taxotere and suffered permanent hair loss, please call Phoenix, Arizona mass tort product liability attorney Steve Leshner for a free consultation.